Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
43. Petri M. Cardiovascular morbidity in the Hopkins Lupus Cohort. In. Atherosclerosis and autoimmunity Ed. Y Schoenfeld, D Harats, G Wick. Elsevier 2001; 249—254.
44. Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hyperlipidemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137—2143.
45. Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women witn systemic lupus erythematosus. Arthritis Rheum 2003; 48: 3159—3167.
46. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythemato-sus. Ann Rheum Dis 2003; 62: 1071—1077.
47. Ettinger WH, Goldberg MD, Applebaum-Bowdwn D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticos-teroids. Am J Med 1987; 83: 503—508.
48. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus ery-thematosus. J Rheumatol 1994; 21: 1261— 1267.
49. Ilowite NT, Samuel P, Ginzler E. Dyslipopro-teinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988; 31: 859—863.
50. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity and anticardiolipin antibodies. Lupus 1997; 6: 533—539.
51. Алекберова ЗС, Попкова ТВ, Насонов ЕЛ, Решетняк ТМ, Озерова ИН, Перова НВ. Липид-белковые системы транспорта холестерина у больных системной красной волчанкой в зависимости от антифосфолипидного синдрома. Терапевт. архив, 1999; 5: 34—38.
52. Formiga F, Meco JF, Pinto X, et al. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients Lupus 2001; 10: 359—363.
53. Borba E, Bonfa E, Vinagre CGC, et al. Chylomicron metabolism is marfedly altered in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1033—1040.
54. Eder HA, Gidez LI. The clinical significance of the plasma high density lipoproteins. Med Clin N Amer 1982; 66: 431—440.
55. Nuttall SL, Heaton S, Piper MK, et al. Cardiovascular risk in systemic lupus erythe-matosus — evidence of increased oxidative stress and dislipidaemia. Rheumatology 2003; 42: 758—762.
56. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887—1893.
57. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082—1085.
58. Petri M, Miller J, Ebert RF. Lipoprotein a (Lp[a]) is predictive of myocardial infarction in SLE. Arthritis Rheum 1995; 38 (Suppl 9): S220.
59. Leandro MI, Atsumi T, Khamashta M, et al. High plasma levels of lipoprotein(a) in patients with primary and secondary antiphospholipid syndrome. Arthritis Rheum. 1996; 39 (Suppl): 96 (abst.)
60. Yamazaki M, Asakura H, Jokaji H, et al. Plasma levels of lipoprotein (a) are elevated in patients with antiphospholipid antibody syndrome. Thromb Haemost 1994; 71: 424—427.
SHS-OOO4.qxd 21.11.2006 16:56 Page З31
31
.ГЛАВА 12. Атеросклеротическое поражение сосудов при системной красной волчанке и АФС
61. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins lupus cohort perspective. Scand J Rheumatol 1996; 25: 191—193.
62. Попкова ТВ, Покровский СН, Алекберо-ва ЗС, Фомичева ОА, Александрова ЕН, Клюквина НГ, Насонов ЕЛ. Липопротеин (а) при системной красной волчанке. Клин. медицина, 1998; 1: 21—24.
63. Font J, Ramos-Casals, Cervera R, et al. Cardiovascular risk factors and long-term outcome of lupus nephritis. Q J Med 2001; 94: 19— 26.
64. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. Q J Med 1999; 92: 211—218.
65. Falaschi F, Ravelli A, Martignon A, et al. Nephrotic-range proteinuria, the major risk factor for early athrosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2001; 43: 1405—1409.
66. Kannell WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAm Med Assoc 1987; 258: 1183—1186.
67. Rahman P, Urowitz MB, Gladman DD, et al. Contribution of traditional risk factor to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999; 26:363—368.
68. Esdale JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham Risk factor fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331—2337.
69. Font J, Jimenez S, Garcia-Criado A, et al. Atherosclerosis in SLE is associated with cumulative disease damage but not with traditional vascular risk factors. ACR 2002; 42 (abst).
70. Marwick TH, Anderson T, Williams MJ, et al. Exercise echocardiography is an accurate and cost-effective technique for detection of coronary artery disease in women. J Am Coll Cardiol 1995; 26: 335—341.
71. Kwok Y, Kim C, Grady D, Segal M, Redberg R. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol 1999; 83: 660—666.
